Assistant Professor•Metabolism|Nutrition|Obesity|Bariatric Surgery•Mom and wife•Bulgarian •Yogi•College football enthusiast•Views my own
UMN-UMich-Miami-UMich & VA
Joined March 2013
- Tweets185
- Following269
- Followers163
- Likes213
Excited to have had the opportunity to contribute to the third edition of the ASMBS Textbook of Metabolic and Bariatric Surgery!
Nadejda Bozadjieva Kramer, PhD retweeted
🚨 New for June, a fresh episode of the #DiabetesBio #podcast!
Featuring:
✨ T-Cell Memory & Weight Cycling
✨ Modulations from Gut-Derived FGF15
✨ + Sweet Talk w Martin Myers, MD, PhD
🎙️Listen at: diabetesbio.libsyn.com
📚Read more: diabetesjournals.org/diabete…
🧠 Share your thoughts in the comments!
@thewilliamslab @Diabetes_ADA @ADA_DiabetesPro @AmDiabetesAssn @KirkMHabegger @nbkramer @UMichMedSchool @UTSWMedCenter
ALT The logo for the DiabetesBio podcast, featuring a red microscope graphic and the insignia of the American Diabetes Association.
Nadejda Bozadjieva Kramer, PhD retweeted
June #DiabetesBio T-cell mem, FGF15, wt loss + #SweetTalk
🍎shorturl.at/pTb5p
🎧shorturl.at/IaO3A
YT shorturl.at/bM1RK
🔗shorturl.at/TdUYP
📰shorturl.at/gA0ZD
@AmDiabetesAssn @thewilliamslab @KirkMHabegger @seeleyrj @nbkramer @ahasty4 #MartinMyers
Our study, published in Diabetes, shows that weight loss involves complex communication between the gut and liver, and understanding how these systems are affected by different weight-loss approaches can help us tailor specific interventions for patients. michiganmedicine.org/health-…
Nadejda Bozadjieva Kramer, PhD retweeted
A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks. Mild dysesthesias noted #weightloss #arthritis investor.lilly.com/news-rele…
Awesome new science by @TarlingVallim
New! Online now: Bile acids regulate lipid metabolism through selective actions on fatty acid absorption dlvr.it/TPmLG5
Nadejda Bozadjieva Kramer, PhD retweeted
Congratulations to the 2026 Laureate Award Recipients | We celebrate the highest achievements in endocrinology across research, clinical care, leadership, mentorship, innovation, and service. View the winners: bit.ly/4876pTF #ENDO2026 #endocrinology
Nadejda Bozadjieva Kramer, PhD retweeted
Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study - Clinical Gastroenterology and Hepatology #MASH #Obesity cghjournal.org/article/S1542…
Nadejda Bozadjieva Kramer, PhD retweeted
My newest paper: Multiple data sets for semaglutide and MASH. Semaglutide may reverse the proteomic signature in people with MASH. No measurable GLP-1 receptor in the liver.
rdcu.be/ew8oR
Nadejda Bozadjieva Kramer, PhD retweeted
Thanks to the Endocrine Society for the invitation. Bariatric surgery is the most efficacious treatment for obesity. Because of the discontinuation rates of GLP-1RA and the increase in prevalence of Stage 3 obesity, I think bariatric surgery will continue to have a role.
Great session examining the role of glucagon and glucagon signaling in metabolic disease! #ENDO2025
Nadejda Bozadjieva Kramer, PhD retweeted
🚨 GLP-1s vs Surgery: Who Wins Long Term?
- - -
A new 2-year comparative study from NYU Langone just dropped—and the results are clear:
📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide):
🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)
🔹 Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6%
🔹 Surgery had better HbA1c improvement, too
🔍 Translational Insight:
Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation. But that’s exactly the point:
➡️ If a treatment is regularly interrupted by prior auths, high out-of-pocket costs, or drug shortages, that limits its real-world effectiveness.
➡️ Clinical effectiveness ≠ theoretical efficacy in a vacuum. Access matters.
📌 Bottom line:
For patients with severe obesity (BMI ≥35), bariatric surgery still provides superior long-term outcomes—and it does so reliably, without being derailed by market forces.
Abstract: soard.org/article/S1550-7289…
Excited to be part of #ENDO2025 endocrinenews.endocrine.org/…
Bypass and Beyond: Redefining Roles and Mechanisms of Obesity Treatment at ENDO 2025 endocrinenews.endocrine.org/…
Nadejda Bozadjieva Kramer, PhD retweeted
ACS Clowes Award recipient Dr. Tammy Kindel is helping uncover significant extended benefits after bariatric surgery.
Her project focuses on understanding how bariatric surgery improves heart function in patients with obesity-related heart failure. brnw.ch/21wSGq4
Nadejda Bozadjieva Kramer, PhD retweeted
.@UMichMedSchool professor Nadejda Bozadjieva Kramer has dedicated her career to studying obesity and metabolic dysfunction, conditions that disproportionately affect veterans and increase their risk of diabetes, heart disease and other chronic illnesses. myumi.ch/rA864
ALT photo of Nadejda Bozadjieva Kramer working in her lab, wearing gloves, a lab coat and safety glasses “The longevity and large scale of our work has been made possible by our partnerships with federal agencies. Research like this takes time, considerable time, to measure and explore and adjust. By being able to conduct projects like the one at U-M over decades, we are able to make significant advancements that would not be possible without those dedicated partners.” Nadejda Bozadjieva Kramer, Assistant Professor of Surgery
Nadejda Bozadjieva Kramer, PhD retweeted
Great to meet with @RepDebDingell to advocate for science and @NIH, @NSF and @DeptVetAffairs research funding at the @APSPhysiology Capitol Hill Day. New breakthroughs in biomedical research depend on strong federal support! #APSHillDay2025
